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Two subtypes of G protein-coupled receptors for nucleotides (P 2U and P 2Y purinoreceptors) contain several
conserved positively charged amino acids in the third,
sixth, and seventh putative transmembrane helices
(TMHs). Since the fully ionized form of nucleotides has
been shown to be an activating ligand for both P 2U and
P 2Y purinoceptors (P 2uR and P 2yR), we postulated that
some of these positively charged amino acids are involved in binding of the negatively charged phosphate
groups of nucleotides. To investigate the role of the conserved positively charged amino acids in purinoceptor
function, a series of mutant P 2uR cDNAs were constructed so that lysine 107 and arginine 110 in TMH 3,
histidine 262 and arginine 265 in TMH 6, and arginine
292 in TMH 7 were changed to the neutral amino acid
leucine or isoleucine. The mutated P 2uR cDNAs were
stably expressed in 1321Nl astrocytoma cells and receptor activity was monitored by quantitating changes in
the concentration of intracellular Ca2 + upon stimulation with full (ATP, UTP) or partial (ADP, UDP) P 2uR
agonists. Neutralization of His262 , Arg265, or Arg292
caused a 100-850-fold decrease in the potency of ATP
and UTP relative to the unmutated P 2uR and rendered
ADP and UDP ineffective. In contrast, neutralization of
Lys l07 or Arg llO did not alter the agonist potency or
specificity of the P 2uR. Neutralization of Lys 289 in the
P 2UR, which is expressed as a glutamine residue in the
P 2Y subtype, did not alter receptor activity; however, a
conservative change from lysine to arginine at this
position altered the rank order of agonist potency so
that ADP and UDP were approximately 100·fold more
potent than ATP and UTP. A three-dimensional model
of the P 2uR indicates the feasibility of His262 , Arg265,
and Arg292 interactions with the phosphate groups of
nucleotides.
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part by the payment of page charges. This article must therefore be
hereby marked "advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.

The cDNAs encoding two subtypes of G protein-coupled receptors (GPCRS)1 for extracellular nucleotides have been isolated (1-4) and, based upon the similarities of the predicted
amino acid sequences, these nucleotide receptors apparently
form a new subset within the GPCR superfamily (5). These
receptors, known as P z purinoceptors and recently renamed
P2Y purinoceptors (6), are linked predominantly via the G/Go
and GJG ll families of G proteins to the inhibition of adenylyl
cyclase or the mobilization of intracellular calcium (7, 8). Physiological processes involving G protein-coupled P z purinoreceptors include platelet aggregation and wound healing (9), insulin
secretion (10), mitogenesis (11), vasodilation (12,13), and transepithelial ion transport (14, 15), making these receptors an
intriguing target for pharmacotherapy. For example, clinical
studies in cystic fibrosis patients indicate that local delivery of
ATP or UTP to lung epithelia stimulates chloride secretion and
promotes mucohydration (16), presumably by activating the
P zu subtype ofpurinoceptors. Unfortunately, the lack of stable,
selective agonists and antagonists for the various P 2 purinoreceptor subtypes has hindered further development oftherapeutic applications centered around these receptor molecules. The
work described in this paper used site-directed mutagenesis to
investigate amino acid residues involved in determining the
agonist potency and specificity of the PzuR, an important step
in the process of rational drug design.
EXPERIMENTAL PROCEDURES
Materials-Pfu DNA polymerase was purchased from Stratagene (La
Jolla, CAl. G418 (Geneticin) was purchased from Life Technologies, Inc.
Human astrocytoma (1321N1) cells were obtained from M. L. Toews
(University of Nebraska, Omaha, NE), and a clonal line that was not
responsive to extracellular nucleotides was selected. eDNA encoding
the murine P 2u R was provided by K. D. Lustig and D. Julius (University of California, San Francisco).
Site-directed Mutagenesis of P2vR eDNA-Point mutations in the
murine P 2u R eDNA were made by using enzymatic inverse polymerase
chain reaction as described previously (17). The class 2s restriction
enzyme used was BsmI (New England Biolabs, Beverly, MA). To reduce
the amount of DNA sequencing necessary to confirm the mutation
within the eDNA, an approximately l-kilobase pair BstEIIIAfllI fragment containing the point mutation was removed and used to replace a
similar fragment in the wild type receptor cDNA. All mutations were
verified by double-stranded dideoxy sequencing (18).
Receptor Expression in Mammalian Cells-To generate stable transfectants expressing the mutant P 2uRs, a 2.4-kilobase pair HindlIVNotI
fragment encompassing nearly the entire receptor cDNA was excised
from each mutant construct in the pBluescript vector and subcloned
into the mammalian expression vector pRclCMV (Invitrogen, San
Diego, CAl. 1321N1 cells were stably transfected with the wild type or
mutant pRclCMV-P2uR plasmids by electroporation as described previously for the transfection ofK562 human leukemia cells with pRclCMVP2uR (7). Transfected 1321N1 cells were selected in growth medium
(Dulbecco's modified Eagle's medium, 5% fetal bovine serum, 100
units/ml penicillin, and 100 ILg/ml streptomycin) containing 500 ILg/ml
G418 and maintained in growth medium containing 100 ILg/ml G418 at
37 DC in a humidified atmosphere of 5% CO 2 and 95% air. Clonal cell
lines were isolated and assayed for P 2uR activity by quantitating
changes in the concentration of cytoplasmic free calcium ([Ca2+J,l upon
stimulation with extracellular nucleotides. Preincubation oftransfected
1321N1 cells with apyrase (2 units/mll to hydrolyze endogenously released ATP (3) had no affect on wild type or mutant P 2uR activity and,
therefore, was not used in this study.
1 The abbreviations used are: GPCR, G protein-coupled receptor;
P2uR, P2U purinoceptor; TMH, transmembrane helix.
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.FIG. ~. Sequence alignment of the murine P 2Ut human P 2Ut chick P 2Y' and bovine Al adenosine receptor. Amino acids that form the
thIrd, sIxth, and seventh TMHs are shown. Altered amino acids are underlined, and the position within the murine receptor sequence is indicated
above each mutagenized residue. Hydropathicity analysis and two-dimensional modeling of the P 2uR indicated that the altered amino acids are
located near the plasma membrane-extracellular interface.

Calcium Measurements-[Ca 2 +l, was measured by dual excitation
spectrofluorometric analysis of cell suspensions loaded with fura-2 as
described previously (19, 20) and assayed in 10 mM Hepes-buffered
saline (pH 7.4) containing 1 mM CaCl2 and 1 mM MgCl 2 unless indicated
otherwise. Concentration response data were analyzed with the Prism
curve-fitting program (GraphPAD, San Diego, CAl.
Molecular Modeling-Construction of the P 2uR three-dimensional
model was based on the following five criteria used to model neurotransmitter GPCRs (21). 1) Hydropathicity analysis and sequence
alignment with highly conserved amino acids in other GPCRs were
used to select regions of the receptor as probable transmembrane a-helices. 2) A model for bacteriorhodopsin based on high resolution electron
cryomicroscopy was used as a template to position the sixth and seventh
anti-parallel a-helices of the murine P 2uR. 3) The helices were oriented
so that highly conserved residues and charged residues faced the central cleft of the receptor, as is the case for bacteriorhodopsin. 4) The
peptide backbone dihedral angles, cf> and 1/1, were -63.0° and -45.3°,
respectively, which is consistent for a-helices in a hydrophobic environment. 5) Energy minimalization was performed by using the Kollmann
force field analysis in SYBYL (TRIPOS, St. Louis, MO) to optimize the
packing of the model.
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RESULTS AND DISCUSSION

The ligand binding sites of most GPCRs, with the possible
exception of the glycoprotein and peptide hormone receptors,
appear to be located in the transmembrane a-helical regions
(22, 23). With this in mind and since the fully ionized form of
nucleotides has been shown to be an agonist for both P 2U and
P 2Y purinoceptors (19,24,25), we postulated that several of the
positively charged amino acids in the putative transmembrane
helices of G protein-coupled purinoceptors that are conserved
between the P2U and P2Y subtypes may be responsible for
binding the negatively charged phosphate groups of the nucleotide ligands.
Sequence alignment of the murine P 2uR, human P 2uR, and
chick P 2yR indicated that five positively charged amino acids
(Lys 107, Arg llO , His 262 , Ar~65, and Ar~92) near the plasma
membrane-extracellular interface ofTMH 3, TMH 6, and TMH
7 were conserved with only a modest change (from Ar~65 to
Lys) occurring in the P 2y subtype (Fig. 1). The adenosine Al
receptor lacks these lysine and arginine residues (Fig. 1), although histidine residues in TMH 6 and TMH 7 of this receptor
are involved in ligand binding (26). The conserved positively
charged amino acids in TMH 6 and TMH 7 are close (within 1-5
amino acids) to prolines or glycines that have been implicated
in forming hinges within transmembrane a-helices as well as
kinks and turns (27, 2S). These perturbations of the a-helix
caused by prolines or glycines could serve to create a ligand
binding pocket involving juxtaposing residues (29).
To investigate the role of the conserved positively charged
amino acids in nucleotide receptor function, we constructed a
series of mutant cDNAs that encode P 2U R proteins with single
amino acid substitutions. Concentration response curves generated for the wild type and mutant P 2uRs expressed in
1321N1 cells indicate that His 262 , Arg265 , and Ar~92 are important for establishing the agonist potency and specificity of
the P 2UR. Neutralization of His 262 , Ar~65, or Ar~92 by substitution with the uncharged amino acid leucine in each case
caused a 100-S50-fold decrease in the potency ofATP and UTP
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75
50
25
0

[NUCLEOTIDE], log M
FIG. 2. Agonist stimulation of intracellular calcium mobilization in 1321Nl cells transfected with wild type or mutant P 2uR
constructs. Cells stably transfected with wild type or mutant P 2u R
cDNAs were assayed for P2uR activity by quantitating changes in the
concentration of cytoplasmic free calcium ([Ca2+],) in response to the
indicated concentration of ATP, UTP, ADP, or UDP. Data are expressed
as a percentage ofthe maximal increase in [Ca 2+l, elicited by the most
effective ligand for each receptor construct and represent the mean :±:
S.E. of three experiments. The maximal increase in [Ca 2+l, obtained for
the wild type receptor and each mutant construct ranged from 200-500
nM, except for mutant Lys269 -> Arg, which exhibited a maximal increase of 90 nM. The average resting [Ca2+l, was 80-150 nM for all
constructs.

without decreasing the efficacy of these ligands relative to the
wild type receptor (Fig. 2). ADP and UDP, which are partial
agonists ofthe wild type P 2uR (Fig. 2), were ineffective agonists
of the His 262 , Ar~65, and Ar~92 mutants at concentrations as
high as 3 mM (Fig. 2). Neutralization of a nonconserved positively charged residue in TMH 7 (Lys289 ---> He) as well as the 2
conserved positively charged residues in TMH 3 (Lys I07 ---> He
and Arg110 ---> Leu) had little effect on the agonist potency or
specificity of the P 2uR (Fig. 2), indicating that these residues
are not critical for receptor activation.
Previous studies with the P 2uR in murine macrophages suggest that this receptor is activated by both ATp4 - and
MgATp 2- but that ATp4 - is 10 times more potent than
MgATp2- (apparent K o.5 values were 0.65 /LM and 6.5 /LM,
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TABLE I

EC50 values and slope factors of ATP for wild type and
mutant P2U purinoceptors
The values are derived from concentration response curves as described in Fig. 2 and are generated from cells incubated in the presence
(+) or absence (-) of 1 mM CaCl 2 and 1 mM MgCI 2. EDTA (0.1 iLM) was
added to the media of cells incubated in the absence of divalent cations.
The data represent the mean ± S.E. of three experiments.
EC 50 values (/LM)

Divalent cations

Wild type P2UR
His 262 -> Leu
Arg>65 -> Leu
Arg>92 -> Leu

Slope factor

+

0.85
11.7
178
209

±
±
±
±

0.13
1.0
76
25

1.00
105
457
851

± 0.15
± 20
± 118
± 160

+

0.72
1.00
0.55
1.85

±
±
±
±

0.08 0.88 ± 0.12
0.20 0.95 ± 0.18
0.18 1.22 ± 0.30
0.28 2.29 ± 0.37

FIG. 3. Molecular model of the P 2uR sixth and seventh TMHs
showing the putative ATP binding site. Shown is a space-filling
model of amino acid residues (highlighted in fuchsia) that are thought
to interact with the negatively charged phosphate residues of ATP. The
viewing direction is in the plane of the plasma membrane and within
the central cleft of the receptor. ATP is colored by atom types: white,
carbon; red, oxygen; orange, phosphorus; dark blue, nitrogen; light blue,
hydrogen.

respectively) (30). Therefore, it was possible that the rightward
shift in the concentration response curves observed for the
His 262 -i> Leu, Arg265 -i> Leu, and Arg292 -i> Leu mutants was
caused by a selective decrease in receptor affinity for the fully
ionized nucleotide. Activation of these mutant P 2uRs in the
absence of extracellular divalent cations, however, indicated
that ATp4 - is still the most potent form of agonist and that the
potency of ATp4 -, relative to total ATP, may be enhanced at
these mutant receptors (Table I).
Although neutralization of Lys289 by substitution with isoleucine had little effect on the agonist potency or specificity of
the P 2u R, a conservative substitution of Lys289 with arginine
shifted the agonist potency so that ADP and UDP were more
effective agonists than ATP and UTP (Fig. 2). Relative to the
wild type P 2uR, the potencies of ADP and UDP were increased

by 4- and 7-fold, respectively, whereas the potencies of ATP and
UTP were decreased by 300- and 26-fold, respectively, for the
Lys289 -i> Arg mutant. The efficacy of all four ligands, however,
was reduced compared to the wild type receptor (Fig. 2), which
could be due to a change in the receptor's tertiary structure
introduced by the Lys289 -i> Arg mutation or a low expression
level of this mutant receptor. Nonetheless, the altered rank
order of agonist potency of the Lys289 -i> Arg mutant cannot be
explained by a low level of receptor expression and strongly
suggests that this conservative mutation affects ligand binding
and not a subsequent step in the signaling pathway.
Interestingly, Lys289, which is conserved in the human and
murine P 2u R homologs, is instead the neutral amino acid glutamine in the chick P 2yR (Fig. 1). Assuming that the phosphate
docking site in these nucleotide receptor subtypes is the same,
this could explain why neutralization of Lys289 in the P2UR did
not alter receptor activity and suggests that the Lys289 residue
is not directly involved in ligand binding. However, the finding
that the Lys289 -i> Arg mutation altered the rank order of
agonist potency of the P 2uR could suggest that Lys289 is positioned close enough to the ligand binding pocket so that substitution of this residue with the slightly larger arginine residue is able to interfere with normal ligand binding.
Molecular modeling of the P2UR sixth and seventh transmembrane a-helical regions indicated the feasibility of His 262 ,
Arg265 , and Ar~92 interactions with the negatively charged
phosphate residues of ATP (Fig. 3). Although ligand binding
could not be directly demonstrated in this paper, due to the lack
of a reliable assay, the finding that neutralization of His 262 ,
Arg265 , and Ar~92 decreased the potency but not the efficacy of
ATP and UTP suggests that ligand binding is being affected.
Furthermore, the observation that the agonist potency of both
ATP and UTP were affected equally by these mutations supports the hypothesis that His 262 , Ar~65, and Ar~92 interact
with the phosphate residues rather than the purine or pyrimidine group of these nucleotide ligands. Unlike the P 2U purinoceptor subtype, the P 2Y subtype is not activated by the pyrimidine nucleotides UTP or UDP. Further mutagenesis studies as
well as the creation of P 2UIP 2Y chimeric receptors should help
to delineate which regions of these nucleotide receptors are
responsible for selectivity of the nucleoside group.
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